

<b>FORM D</b>
Notice of Exempt Offering of Securities

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION  
Washington, D.C.**

<b>OMB APPROVAL</b>
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

**1. Issuer's Identity**

CIK (Filer ID Number) <b>0001553643</b>	Previous Name(s) <input type="checkbox"/> None <b>Camp Nine, Inc.</b>	Entity Type <input checked="" type="radio"/> Corporation <input type="radio"/> Limited Partnership <input type="radio"/> Limited Liability Company <input type="radio"/> General Partnership <input type="radio"/> Business Trust <input type="radio"/> Other
Name of Issuer <b>RELMADA THERAPEUTICS, INC.</b>	<b>CAMP NINE, INC.</b>	
Jurisdiction of Incorporation/Organization <b>NEVADA</b>		
Year of Incorporation/Organization <input checked="" type="radio"/> Over Five Years Ago <input type="radio"/> Within Last Five Years (Specify Year) <input type="text"/> <input type="radio"/> Yet to Be Formed		

**2. Principal Place of Business and Contact Information**

Name of Issuer <b>RELMADA THERAPEUTICS, INC.</b>			
Street Address 1 <b>750 THIRD AVENUE</b>		Street Address 2 <b>9TH FLOOR</b>	
City <b>NEW YORK</b>	State/Province/Country <b>NEW YORK</b>	ZIP/Postal Code <b>10017</b>	Phone No. of Issuer <b>212-547-9591</b>

**3. Related Persons**

Last Name <b>Traversa</b>	First Name <b>Sergio</b>	Middle Name	
Street Address 1 <b>750 Third Avenue</b>	Street Address 2 <b>9th Floor</b>		
City <b>New York</b>	State/Province/Country <b>NEW YORK</b>	ZIP/Postal Code <b>10017</b>	
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter

Clarification of Response (if Necessary)

Last Name <b>Casamento</b>	First Name <b>Charles</b>	Middle Name
Street Address 1 <b>750 Third Avenue</b>	Street Address 2 <b>9th Floor</b>	
City	State/Province/Country	ZIP/Postal Code

New York NEW YORK 10017

Relationship: [ ] Executive Officer [x] Director [ ] Promoter

Clarification of Response (if Necessary)

Last Name: Kelly, First Name: Paul, Middle Name:
Street Address 1: 750 Third Avenue, Street Address 2: 9th Floor
City: New York, State/Province/Country: NEW YORK, ZIP/Postal Code: 10017

Relationship: [ ] Executive Officer [x] Director [ ] Promoter

Clarification of Response (if Necessary)

Last Name: Shenouda, First Name: Maged, Middle Name:
Street Address 1: 750 Third Avenue, Street Address 2: 9th Floor
City: New York, State/Province/Country: NEW YORK, ZIP/Postal Code: 10017

Relationship: [ ] Executive Officer [x] Director [ ] Promoter

Clarification of Response (if Necessary)

4. Industry Group

- Agriculture
Banking & Financial Services
Business Services
Energy
Health Care
Manufacturing
Real Estate
Retailing
Restaurants
Technology
Travel
Other

## 5. Issuer Size

### Revenue Range

- No Revenues
- \$1 - \$1,000,000
- \$1,000,001 - \$5,000,000
- \$5,000,001 - \$25,000,000
- \$25,000,001 - \$100,000,000
- Over \$100,000,000
- Decline to Disclose
- Not Applicable

### Aggregate Net Asset Value Range

- No Aggregate Net Asset Value
- \$1 - \$5,000,000
- \$5,000,001 - \$25,000,000
- \$25,000,001 - \$50,000,000
- \$50,000,001 - \$100,000,000
- Over \$100,000,000
- Decline to Disclose
- Not Applicable

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

<input type="checkbox"/>	Rule 504(b)(1) (not (i), (ii) or (iii))	<input type="checkbox"/>	Rule 505
<input type="checkbox"/>	Rule 504 (b)(1)(i)	<input checked="" type="checkbox"/>	Rule 506(b)
<input type="checkbox"/>	Rule 504 (b)(1)(ii)	<input type="checkbox"/>	Rule 506(c)
<input type="checkbox"/>	Rule 504 (b)(1)(iii)	<input type="checkbox"/>	Securities Act Section 4(a)(5)
<input type="checkbox"/>		<input type="checkbox"/>	Investment Company Act Section 3(c)

## 7. Type of Filing

- New Notice      Date of First Sale             First Sale Yet to Occur
- Amendment

## 8. Duration of Offering

Does the Issuer intend this offering to last more than one year?       Yes       No

## 9. Type(s) of Securities Offered (select all that apply)

- Pooled Investment Fund Interests       Equity
- Tenant-in-Common Securities       Debt
- Mineral Property Securities       Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon
- Exercise of Option, Warrant or Other Right to Acquire Security       Other (describe)

## 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?       Yes       No

Clarification of Response (if Necessary)

## 11. Minimum Investment

Minimum investment accepted from any outside      \$       USD

investor

## 12. Sales Compensation

Recipient

Recipient CRD Number

None

Alexander Capital, LP

40077

(Associated) Broker or Dealer

None

(Associated) Broker or Dealer CRD Number

None

Street Address 1

Street Address 2

17 STATE STREET

5TH FLOOR

City

State/Province/Country

ZIP/Postal Code

NEW YORK

NEW YORK

10004

State(s) of Solicitation

All States

Foreign/Non-US

ALABAMA

COLORADO

CONNECTICUT

FLORIDA

GEORGIA

MASSACHUSETTS

NEW JERSEY

NEW YORK

PENNSYLVANIA

RHODE ISLAND

SOUTH CAROLINA

TEXAS

VIRGINIA

## 13. Offering and Sales Amounts

Total Offering Amount \$ 6890000 USD  Indefinite

Total Amount Sold \$ 6890000 USD

Total Remaining to be Sold \$ 0 USD  Indefinite

Clarification of Response (if Necessary)

## 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

65

## 15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$  USD  Estimate  
Finders' Fees \$  USD  Estimate

Clarification of Response (if Necessary)

**Not included in the sales commission amount is a non-accountable 1% allowance (\$58,540) for expenses paid to the agent. The agent also received warrants to purchase 779,333 shares of common stock of the issuer.**

## 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$  USD  Estimate

Clarification of Response (if Necessary)

**In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.**

## Signature and Submission

**Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.**

### Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
RELMADA THERAPEUTICS, INC.	/s/ Sergio Traversa	Sergio Traversa	CEO	2017-10-05

